Medtech Insight RSS Feed - Infectious Diseases

Vedanta’s Phase III For Recurrent C. Diff Gets Nod To Continue

Joseph Haas — Fri, 03 Apr 2026 21:31:22 +0000

Vedanta Biosciences has gotten a go-ahead from the independent data monitoring committee overseeing its RESTORATiVE303 Phase III trial of VE303, a live biotherapeutic product, for prevention of recurr

Acadia CEO Led The Company To A Key Goal In A Challenging Year For Biopharma

Mandy Jackson — Fri, 03 Apr 2026 19:02:35 +0000

Last year was tough for the biopharmaceutical industry as companies struggled to understand the implications of policy changes under the Trump administration, adding another set of challenges for CEOs

Atrogi Bets On Muscle Preservation And Exercise Mimetics To Drive Obesity Push

Sushmita Panda — Fri, 03 Apr 2026 13:02:58 +0000

Sweden‑based Atrogi is targeting a different corner of the obesity market, developing drugs designed to preserve muscle mass and mimic the effects of exercise rather than simply suppressing appetite.

Lipocine’s Oral Formulation Of Zulresso Fails Postpartum Depression Trial

Manas Mishra — Fri, 03 Apr 2026 12:55:17 +0000

Lipocine’s bid to replicate the effects of Sage Therapeutics’ now-discontinued postpartum depression (PDD) drug, Zulresso (brexanolone), in pill form has stumbled at the final hurdle. On April 2, th

Executives On The Move: Five CEOs And Six CFOs Among This Week’s Changes

Fri, 03 Apr 2026 11:07:19 +0000

Glenmark Reshapes US Ryaltris Strategy, Steps Away From Hikma Tie-Up

Anju Ghangurde — Fri, 03 Apr 2026 09:43:38 +0000

Six years after sealing an exclusive licensing agreement with Hikma to commercialize Ryaltris (olopatadine HCl/mometasone furoate nasal spray) in the US, Glenmark has now decided to directly drive bra

LG Builds Global Oncology Ambitions With Novel Frontier Asset

Ian Haydock — Fri, 03 Apr 2026 01:48:27 +0000

South Korea’s LG Chem is furthering its global oncology ambitions through the acquisition of exclusive worldwide development and commercialization rights outside of greater China to FMC-220, US proteo

Trump 100% Tariffs On Drugs Make Big Pharma’s Negotiations A Smart Play

Jessica Merrill — Thu, 02 Apr 2026 22:39:00 +0000

The Trump administration announced 100% tariffs on some pharmaceuticals and pharmaceutical ingredients imported into the US on April 2 following a year-long Section 232 investigation into the sector.

March Surge Lifts First Quarter M&A Totals To Recent Highs

Joseph Haas — Thu, 02 Apr 2026 21:38:18 +0000

The expected uptick in merger-and-acquisition activity during 2026 got off to a sporadic start in the first quarter, until March brought a spring-like bursting of volume and valuation, according to

Beam Preps For Commercialization Of Risto-Cel As Full Data Published

Alaric DeArment — Thu, 02 Apr 2026 20:10:42 +0000

If it wins US Food and Drug Administration approval, Beam Therapeutics’ ristoglogene autogetemcel (risto-cel) will be a latecomer on the scene of genetic medicines for sickle cell disease (SCD), but i

Roivant Shrugs Off Batoclimab Phase III Failure in TED

Manas Mishra|Jessica Merrill — Thu, 02 Apr 2026 14:48:10 +0000

Immunovant announced that its neonatal fragment crystallizable receptor (FcRn) inhibitor batoclimab has failed to meet the endpoints of two Phase III trials in thyroid eye disease (TED), but the failu

Alto’s Schizophrenia Failure Reinforces Its Depression Drive

Alexandra Shimmings — Thu, 02 Apr 2026 12:11:27 +0000

Alto Neuroscience has jettisoned plans to develop its PDE4 inhibitor, ALTO-101, at least in its current form, after it failed in a Phase IIb study in cognitive impairment associated with schizophrenia

Amid Iran War, India Tries To Keep Lights On With Duty Cuts

Vibha Ravi — Thu, 02 Apr 2026 09:43:23 +0000

The Indian government has acceded to the pharma industry’s requests to cut import duties on petrochemical products, providing some respite from a cost escalation due to disruptions in freight movement

Tanabe Eyes US NDA For Dersimelagon Following Positive Phase III Results In Rare Derma Disorders

Lisa Takagi — Thu, 02 Apr 2026 01:30:35 +0000

Positive top-line Phase III results for Tanabe Pharma’s (formerly Mitsubishi Tanabe Pharma) dersimelagon (MT-7117) in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) have prompte

Korsana Plans To Take On Roche’s Trontinemab In Alzheimer’s

Joseph Haas — Wed, 01 Apr 2026 20:50:29 +0000

Korsana Biosciences announced on April 1 that it will reverse merge with troubled Cyclerion Therapeutics in a transaction that will coincide with a syndicated fundraising of roughly $380m, providing s

With Centessa, Lilly Buys Broad Pathway Potential

Jessica Merrill — Wed, 01 Apr 2026 19:50:47 +0000

The initial focus of Eli Lilly’s $6.3bn acquisition of Centessa Pharmaceuticals is on the company’s lead asset, the orexin receptor 2 (OX2R) agonist cleminorexton (formerly ORX750), for its potential

FDA Pushes Back Action Date For Orca-T Due To New CMC Information

Alaric DeArment — Wed, 01 Apr 2026 19:31:41 +0000

Orca Bio has hit a regulatory snag as it seeks to bring its allogeneic T-cell therapy, Orca-T, to market, delaying a potential approval by three months. The Menlo Park, Calif.-based biotech said April

Connect Has A Best-In-Class Anti-IL-13 In Eczema, But Won’t Be Taking On Apogee Yet

Andrew McConaghie — Wed, 01 Apr 2026 17:16:09 +0000

New Phase III data from China has convinced Connect Biopharma and its partner Simcere that their IL-13 inhibitor candidate, rademikibart, has a best-in-class efficacy profile in the highly competitive

Oral Obesity Battle Begins As FDA Approves Lilly’s Foundayo

Alaric DeArment|Mary Jo Laffler — Wed, 01 Apr 2026 16:56:49 +0000

The oral obesity market competition is about to take off, with the US Food and Drug Administration’s approval of Lilly’s Foundayo (orforglipron) on April 1 for adults with obesity or overweight with w

Has Novo Nordisk ‘Killed The Noise’ On Semaglutide Pricing In India?

Anju Ghangurde — Wed, 01 Apr 2026 09:26:01 +0000

Days after cut-price generic semaglutide versions flooded the Indian market, Novo Nordisk has taken the bull by its horns, managing, perhaps, in part, to ‘kill the noise on pricing’ as one industry he